Ultimovacs ASA Reports on Voting Rights Ahead of Meeting
Ultimovacs ASA Shares Voting Rights Information
Oslo, January 6, 2025: As Ultimovacs ASA prepares for its Extraordinary General Meeting scheduled for January 9, 2025, significant voting rights information has been released. Jónas Einarsson, the esteemed Chair of the Board of Directors, has informed that he has received proxy-based voting rights for a total of 8,020,964 shares. This accounts for an impressive 23.31% of the overall voting rights within the company.
Details Regarding the Proxies
The proxies obtained by Einarsson are exclusively valid for use at the upcoming extraordinary meeting. This strategic move reflects the company's commitment to transparency and shareholder engagement. With these voting rights, the shareholders are empowered to have a say in critical decisions that will shape the company's future.
Compliance with Regulations
This disclosure aligns with the requirements set forth in section 5-12 of the Norwegian Securities Trading Act. Ultimovacs ASA places a strong emphasis on compliance and transparency, ensuring that all relevant information is communicated to stakeholders in a timely manner.
Future Engagement Initiatives
As part of its ongoing vision to foster open communication with shareholders, Ultimovacs ASA is dedicated to providing guests at the meeting an opportunity to voice their perspectives during discussions. Initiatives like these signify a healthy dialogue between the management and shareholders, contributing positively to the company’s governance.
Key Contacts for Ultimovacs ASA
For additional insights and clarifications regarding the voting rights, interested parties can reach out to Jonás Einarsson, Chair of the Board of Directors, at je@radforsk.no or by calling +47 480 96 355.
Chief Financial Officer's Contact
Hans Vassgård Eid, the CFO and Interim CEO of Ultimovacs ASA, is also available for inquiries. He can be contacted via email at hans.eid@ultimovacs.com or by phone at +47 482 48632.
Frequently Asked Questions
What is the purpose of the Extraordinary General Meeting?
The meeting serves to discuss important company matters and provides shareholders the opportunity to cast their votes on various proposals.
How are proxy voting rights used in the meeting?
Proxy voting allows shareholders unable to attend the meeting to designate someone else to vote on their behalf, ensuring their voices are heard.
What percentage of voting rights does Jónas Einarsson represent?
Jónas Einarsson holds proxy voting rights for 8,020,964 shares, which equates to 23.31% of the total voting rights of Ultimovacs ASA.
How can shareholders participate in the discussions?
Shareholders are encouraged to attend the meeting and engage in discussions to express their views and opinions.
Where can I find more information about Ultimovacs ASA?
For further details, shareholders can refer to the company's official website or reach out to the provided contact persons.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.
